The massively parallel sequencing technology known as Next-generation sequencing (NGS) has revolutionized the biological sciences.The technologies surrounding it are developing and progressing every day. It replaces the Sanger Sequencing method and is more time and cost-effective, resulting in better sequencing output. While the Sanger method only sequences a single DNA fragment at a time, NGS is massively parallel, sequencing millions of fragments simultaneously per run. Due to this rapid and efficient process, DNA sequencing technology-based strategies have paved the way for the molecular prediction of human diseases with a precision medicine approach.
NGS has been applied increasingly in cancer genomics research over the past decade. More recently, NGS has been adopted in clinical oncology to advance personalized treatment of cancer. NGS has also been used actively during the COVID-19 pandemic in monitoring changes to the SARS-CoV-2 genome.
There are, however, an increasing number of examples whereby NGS is employed to discover novel pathogens, and these cases provide precedent for the use of NGS in microbial diagnostics. NGS has many advantages over traditional microbial diagnostic methods, such as unbiased rather than pathogen-specific protocols, ability to detect fastidious or non-culturable organisms, and ability to detect co-infections.
Future directions in precision medicine consist of the empowerment of NGS technologies with parallel approaches, including artificial intelligence (AI), machine learning (ML) methods and deep learning (DL) methods.
Group Futurista’s “Future of Next Generation Sequencing '' aims to bring together renowned leaders to discuss crucial medical technology and provide detailed insights on single-cell sequencing, spatial sequencing technologies and discuss the latest technology trends.